Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Lexicon Pharmaceuticals ( (LXRX) ) has issued an update.
On November 6, 2025, Lexicon Pharmaceuticals filed a prospectus supplement related to its Open Market Sale Agreement with Jefferies LLC, allowing the sale of up to $75 million in common stock. As of that date, no sales had been made under the agreement, and a legal opinion on the validity of the shares was issued by Vinson & Elkins L.L.P.
The most recent analyst rating on (LXRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.
Spark’s Take on LXRX Stock
According to Spark, TipRanks’ AI Analyst, LXRX is a Neutral.
The overall stock score is driven by strong earnings call results and positive technical indicators, despite financial performance challenges and valuation concerns. The company’s strategic repositioning and revenue growth are significant positives, but profitability and cash flow issues remain critical risks.
To see Spark’s full report on LXRX stock, click here.
More about Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a Delaware-based company operating in the pharmaceutical industry, focusing on the development and commercialization of innovative therapies for human disease.
Average Trading Volume: 2,274,758
Technical Sentiment Signal: Hold
Current Market Cap: $483.3M
For a thorough assessment of LXRX stock, go to TipRanks’ Stock Analysis page.